Clinical Trials and Evolving Treatment Paradigms in Urologic Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 1 August 2026 | Viewed by 9
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue will highlight innovations in the design, execution, and interpretation of clinical research in urologic cancers, including prostate, bladder, kidney, and testicular malignancies. As therapeutic options expand and clinical management becomes more nuanced, staying current with trial data and evolving treatment strategies is critical for oncology practice.
We welcome submissions that contribute to a comprehensive understanding of clinical progress in urologic oncology—ranging from pivotal clinical trials, subgroup analyses, meta-analyses, and treatment sequencing strategies to reviews of emerging therapeutic approaches. The issue also invites contributions on new frontiers such as biomarker integration, patient selection strategies, and the potential clinical role of artificial intelligence and digital tools.
This collection aims to bring together a wide range of research that reflects the dynamic and multidisciplinary nature of modern urologic oncology, offering insights for clinicians, researchers, and policy makers involved in the care of patients with genitourinary malignancies.
Urologic cancers continue to represent a significant proportion of the global cancer burden. Rapid developments in systemic therapies, trial designs, and risk-adapted strategies are reshaping how these malignancies are managed across different disease stages. Clinicians are increasingly challenged to stay informed on evolving evidence while personalizing care based on individual patient and disease characteristics.
We are pleased to invite you to contribute to the Special Issue, “Clinical Trials and Evolving Treatment Paradigms in Urologic Cancers,” in Cancers. This issue aligns closely with the journal’s clinical and translational mission and seeks to provide a platform for original research and critical reviews that reflect the current and future direction of genitourinary oncology.
This Special Issue aims to feature timely, high-quality contributions that inform best practices and highlight emerging trends in urologic cancer treatment. The goal is to assemble a broad yet cohesive body of work that reflects innovation across disciplines.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Clinical trials and study design in urologic cancers;
- Systemic therapy advances (e.g., hormonal, immune, and targeted therapies);
- Biomarkers and patient selection in clinical practice;
- Meta-analyses and evidence syntheses;
- Treatment sequencing and combination strategies;
- Emerging use of AI and digital technologies in urology;
- Patient-reported outcomes and quality of life measures;
- Evolving standards of care and practice-changing data.
We look forward to receiving your contributions.
Dr. Zin War Myint
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urologic cancers
- clinical trials
- prostate cancer
- bladder cancer
- kidney cancer
- testicular cancer
- systemic therapy
- meta-analysis
- biomarkers
- oncology innovation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
